Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma
October 16, 2014 at 07:35 AM EDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced encouraging topline data from its Phase 2a exploratory study of duvelisib ...